ERBB2 and breast cancer: Trastuzumab is a recombinant humanized monoclonal antibody selective for the extracellular domain of the human epidermal growth factor receptor protein (HER2), whose overexpression in 20–30% of breast cancers (BC) [1] is associated with poor prognosis [2].